Department of Clinical Laboratory, 26447Peking university First Hospital, Beijing, China.
Werfen Medical Device Trading (Beijing) Co., Ltd, Beijing, China.
Clin Appl Thromb Hemost. 2022 Jan-Dec;28:10760296221118483. doi: 10.1177/10760296221118483.
Evaluate the technical performance of the pre-analytical hemolysis-icterus-lipemia (HIL) check module on the ACL-TOP-750. 8433 routine coagulation samples were evaluated for HIL, the presence of clotting and low sample volume by both visual inspection and the pre-analytical HIL check module on the ACL-TOP-750. 7726 samples were in agreement with both methods and 707 were not consistent. 356 samples with low volume were identified by visual inspection and 920 by the instrument (2.7 mL threshold). Visual inspection identified 56 lipemic samples while 13 of those with moderate or high lipemia were identified by the instrument. Visual inspection identified 47 hemolyzed samples while 7 with moderate or high hemolysis were identified by the instrument. Both visual inspection and the instrument identified 36 icteric samples. For triglyceride concentration and bilirubin concentration, there was good correlation between the ACL-TOP-750 and the DXC800 biochemistry analyzer. Among 30 samples with varying amounts of clotting, 27 were discovered by visual inspection and 3 were discovered by the instrument. The pre-analytical check module on the ACL-TOP-750 improved the detection rate of samples below the target 2.7 mL volume, and the accuracy in detection of HIL. However, the automated method could not replace visual assessment of clotting in samples.
评估 ACL-TOP-750 前分析溶血-黄疸-脂血(HIL)检查模块的技术性能。 对 8433 例常规凝血样本进行 HIL、凝血和低样本量的评估,分别通过 ACL-TOP-750 上的目视检查和前分析 HIL 检查模块进行。 7726 个样本与两种方法均一致,707 个样本不一致。 目视检查识别出 356 个低体积样本,仪器识别出 920 个(2.7ml 阈值)。目视检查识别出 56 个脂血样本,而仪器识别出 13 个中重度脂血样本。目视检查识别出 47 个溶血样本,而仪器识别出 7 个中重度溶血样本。目视检查和仪器均识别出 36 个黄疸样本。对于甘油三酯浓度和胆红素浓度,ACL-TOP-750 和 DXC800 生化分析仪之间存在良好的相关性。在 30 个具有不同凝血量的样本中,27 个是通过目视检查发现的,3 个是通过仪器发现的。 ACL-TOP-750 上的前分析检查模块提高了低于目标 2.7ml 体积的样本的检测率,以及 HIL 的检测准确性。然而,自动化方法无法替代对样本凝血的目视评估。